Imaging recognition of multidrug resistance in human breast tumors using 99mTc-labeled monocationic agents and a high-resolution stationary SPECT system

Nuclear Medicine and Biology

Volumn 31, Issue 1, 2004, Pages 53-65

  Liu, Zhonglin ^a   Stevenson, Gail D ^a   Barrett, Harrison H ^a   Kastis, George A ^a   Bettan, Michael ^a,b   Furenlid, Lars R ^a   Wilson, Donald W ^a   Woolfenden, James M ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b SOREQ NUCLEAR RESEARCH CENTER   (Israel)

Author keywords

99mTc sestamibi; 99mTc furifosmin; 99mTc tetrofosmin; Breast tumor; High resolution SPECT; Multidrug resistance

Indexed keywords

FURIFOSMIN TC 99M; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN; TETROFOSMIN TC 99M;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; DRUG SENSITIVITY; FEASIBILITY STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMAGING; MULTIDRUG RESISTANCE; NONHUMAN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 1642451806     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(03)00119-7     Document Type: Article

References (43)

1. Pastan I., Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med. 316:1987;1388-1393.
2. Woodhouse J.R., Ferry D.R. The genetic basis of resistance to cancer chemotherapy. Ann. Med. 27:1995;157-167.
3. Gottesman M.M., Pastan I. The multidrug transporter, a double-edged sword. J Biol Chem. 263:1988;12163-12166.
4. Bellamy W.T. P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol. 36:1996;161-183.
5. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 62:1993;385-427.
6. Germann U.A., Pastan I., Gottesman M.M. P-glycoproteins mediators of multidrug resistance . Semin Cell Biol. 4:1993;63-76.
7. Ling V. P-glycoprotein its role in drug resistance . Am J Med. 99:1995;31-34.
8. Higgins C.V., Callaghan T., Linton K.J., Rosenberg M.F., Ford R.C. Structure of the multidrug resistance P-glycoprotein. Semin Cancer Biol. 8:1997;135-142.
9. Piwnica-Worms D., Chiu M.L., Budding M., Kronauge J.F., Kramer R.A., Croop J.M. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 53:1993;977-984.
10. Ballinger J.R., Muzzammil T., Moore M.J. Technetium-99m-furifosmin as an agent for functional imaging of multidrug resistance in tumors. J Nucl Med. 38:1997;1915-1919.
11. Muzzammil T., Ballinger J.R., Moore M.J. 99mTc-sestamibi imaging of inhibition of the multidrug resistance transporter in a mouse xenograft model of human breast cancer. Nucl Med Commun. 20:1999;115-122.
12. Sun S.S., Hsieh J.F., Tsai S.C., Ho Y.J., Kao C.H. Technetium-99m tetrofosmin mammoscintigraphy findings related to the expression of P-glycoprotein mediated multidrug resistance. Anticancer Res. 20:2000;1467-1470.
13. Muzzammil T., Moore M.J., Ballinger J.R. In vitro comparison of sestamibi, tetrofosmin, and furifosmin as agents for functional imaging of multidrug resistance in tumors. Cancer Biother Radiopharm. 15:2000;339-346.
14. Del Vecchio S., Ciarmiello A., Salvatore M. Scintigraphic detection of multidrug resistance in cancer. Cancer Biother Radiopharm. 15:2000;327-337.
15. Del Vecchio S., Ciarmiello A., Potena M.I., Carriero M.V., Mainolfi C., Botti G., Thomas R., Cerra M., D'Aiuto G., Tsuruo T., Salvatore M. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med. 24:1997;150-159.
16. Del Vecchio S., Ciarmiello A., Salvatore M. Clinical imaging of multidrug resistance in cancer. Q J Nucl Med. 43:1999;125-131.
17. McGoron A.J., Gerson M.C., Biniakiewicz D.S., Roszel N.J., Washburn L.C., Millard R.W. Extraction and retention of technetium-99m Q12, technetium-99m sestamibi, and thallium-201 in isolated rat heart during coronary academia. Eur J Nucl Med. 24:1997;1479-1486.
18. Bernard B.F., Krenning E.P., Breeman W.A., Ensing G., Benjamins H., Bakker W.J., Visser T.J., de Jong M. 99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-Q12 in vitro and in vivo. Nucl Med Biol. 25:1998;233-240.
19. Tunggal J.K., Ballinger J.R., Tannock L.F. Influence of cell concentration in limiting the therapeutic benefit of P-glycoprotein reversal agents. Int J Cancer. 81:1998;741-747.
20. Chen C.C., Meadows B., Regis J., Kalafsky G., Fojo T., Carrasquillo J.A., Bates S.E. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin Cancer Res. 3:1997;545-552.
21. Bakker M., van der Graaf W.T., Piers D.A., Franssen E.J., Groen H.J., Smit E.F., Kool W., Hollema H., Muller E.A., De Vries E.G. 99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours. Anticancer Res. 19:1999;2349-2353.
22. Ballinger J.R., Hua H.A., Berry B.W., Firby P., Boxen I. 99mTc-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant . Nucl Med Commun. 16:1995;253-257.
23. Muzzammil T., Moore M.J., Hedley D., Ballinger J.R. Comparison of (99m)Tc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function. Br J Cancer. 84:2001;367-373.
24. Klein W.P., Barrett H.H., Pang I.W., Patton D.D., Rogulski R.R., Sain J.D., Smith W. FASTSPECT Electrical and mechanical design of a high-resolution dynamic SPECT imager, Conference Record of the 1995 IEEE . Nucl Sci Symp Medd Img. 2:1995;931-933.
25. Kastis G.K., Barber H.B., Barrett H.H., Gifford H.C., Pang I.W., Patton D.D., Sain J.D., Stevenson G.D., Wilson G.W. High resolution SPECT imager for three-dimensional imaging of small animals (abstract). J Nucl Med. 39:(suppl):1998;9P.
26. Liu Z., Kastis G.A., Stevenson G.D., Barrett H.H., Furenlid L.R., Kupinski M.A., Patton D.D., Wilson D.W. Quantitative analysis of acute myocardial infarct in rat hearts with ischemia-reperfusion using a high-resolution stationary SPECT system. J Nucl Med. 43:2002;933-939.
27. Taylor C.W., Dalton W.S., Parrish P.R., Gleason M.C., Bellamy W.T., Thompson F.H., Roe D.J., Trent J.M. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br J Cancer. 63:1991;923-929.
28. Molteni S.N., Seregni E., Botti C., Martinetti A., Ferrari L., Crippa F., Bombardieri E. The breast cancer cell line MCF7 as a model of 99mTc-SestaMIBI, 99mTc-tetrofosmin and 99mTc-Medronate incorporation. Anticancer Res. 19:1999;255-259.
29. Del Vecchio S., Ciarmiello A., Pace L., Potena M.I., Carriero M.V., Mainolfi C., Thomas R., D'Aiuto G., Tsuruo T., Salvatore M. Fractional retention of technetium-99m sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med. 38:1997;1348-1351.
30. Takamura Y., Miyoshi Y., Taguchi T., Noguchi S. Prediction of chemotherapeutic response by Technetium 99m-MIBI scintigraphy in breast carcinoma patients. Cancer. 92:2001;232-239.
31. Piwnica-Worms D., Rao V.V., Kronauge J.F., Croop J.M. Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry. 34:1995;12210-12220.
32. Ballinger J.R., Bannerman J., Boxen I., Firby P., Hartman N.G., Moore M.J. Technetium-99m-tetrofosmin as a substrate for P-glycoprotein in vitro studies in multidrug-resistant breast tumor cells . J Nucl Med. 37:1996;1578-1582.
33. Perek N., Prevot N., Koumanov F., Frere D., Sabido O., Beauchesne P., Dubois F. Involvement of the glutathione S-conjugate compounds and the MRP protein in Tc-99m-tetrofosmin and Tc-99m-sestamibi uptake in glioma cell lines. Nucl Med Biol. 27:2000;299-307.
34. Chen W.S., Luker K.E., Dahlheimer J.L., Pica C.M., Luker G.D., Piwnica-Worms D. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin. Biochem Pharmacol. 60:2000;413-426.
35. Arbab A.S., Koizumi K., Toyama K., Araki T. Uptake of technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 in tumor cell lines. J Nucl Med. 37:1996;1551-1556.
36. Platts E.A., North T.L., Pickett R.D., Kelly J.D. Mechanism of uptake of technetium-tetrofosmin. I Uptake into isolated adult rat ventricular myocytes and subcellular localization . J Nucl Cardiol. 2:1995;317-326.
37. Piwnica-Worms D., Kronauge J.F., Chiu M.I. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium (I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation. 82:1990;1826-1838.
38. Chiu M.L., Kronauge J.F., Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2- methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med. 31:1990;1646-1653.
39. Carvalho P.A., Chiu M.L., Kronauge J.F., Kawamura M., Jones A.G., Holman B.L., Piwnica-Worms D. Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med. 33:1992;1516-1522.
40. Kelly J.D., Forster A.M., Higley B., Archer C.M., Booker F.S., Canning L.R., Chiu K.W., Edwards B., Gill H.K., McPartlin M. Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med. 34:1993;222-227.
41. Munch G., Neverve J., Matsunari I., Schroter G., Schwaiger M. Myocardial technetium-99m-tetrofosmin and technetium-99m-sestamibi kinetics in normal subjects and patients with coronary artery disease. J Nucl Med. 38:1997;428-432.
42. Crankshaw C.L., Marmion M., Luker G.D., Rao V., Dahlheimer J., Burleigh B.D., Webb E., Deutsch K.F., Piwnica-Worms D. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein. J Nucl Med. 39:1998;77-86.
43. Acton P.D., Choi S.R., Plössl K., Kung H.F. Quantification of dopamine transporters in the mouse brain using ultra-high resolution single-photon emission tomography. Eur J Nucl Med Mol Imaging. 29:2002;691-698.